Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 11:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 192 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Term Infants Clear all
Completed Phase 1 Interventional

Open-label Study of Inhaled RVT-1601 in Preterm Infants

NCT04007120
View directory record Official record
Conditions
Respiratory Morbidities of Prematurity (RMP)
Interventions
RVT-1601
Drug
Lead sponsor
Respivant Sciences GmbH
Industry
Eligibility
32 Months to 35 Months
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Oct 22, 2026, 11:57 PM EDT
Recruiting Phase 3 Interventional

Safety and Efficacy of APC-0101 in Preterm Infants With Respiratory Distress Syndrome

NCT06776783
View directory record Official record
Conditions
Respiratory Distress Syndrome, Pre-term Infants
Interventions
APC-0101 (SF-RI 1 surfactant for inhalation combined with a dedicated delivery system), Control
Combination Product · Other
Lead sponsor
Aerogen Pharma Limited
Industry
Eligibility
1 Hour to 24 Hours
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
18
States / cities
Little Rock, Arkansas • La Jolla, California • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 22, 2026, 11:57 PM EDT
Completed Not applicable Interventional

Donor Breast Milk and Breastfeeding Rates

NCT04572581
View directory record Official record
Conditions
Breastfeeding, Exclusive, Breastfeeding
Interventions
Donor Breast Milk
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Up to 3 Days
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Oct 22, 2026, 11:57 PM EDT
Enrolling by invitation Phase 2Phase 3 Interventional

An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007

NCT06075537
View directory record Official record
Conditions
Mucopolysaccharidosis II
Interventions
tividenofusp alfa
Drug
Lead sponsor
Denali Therapeutics Inc.
Industry
Eligibility
Up to 18 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
8
States / cities
Oakland, California • Chicago, Illinois • Hackensack, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 22, 2026, 11:57 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Growth and Tolerance of Healthy Term Infants Fed Cow's Milk-Based Infant Formulas

NCT02860026
View directory record Official record
Conditions
Growth
Interventions
Marketed cow's milk-based infant formula, Cow's milk-based infant formula with added nutrients
Other
Lead sponsor
Mead Johnson Nutrition
Industry
Eligibility
10 Days to 14 Days
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
17
States / cities
Birmingham, Alabama • Dothan, Alabama • Fayetteville, Arkansas + 14 more
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Oct 22, 2026, 11:57 PM EDT
Completed Phase 3 Interventional Results available

Long-term Safety of Lumacaftor/Ivacaftor in Participants With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation

NCT04235140
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
LUM/IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Months and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
20
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 22, 2026, 11:57 PM EDT
Completed Phase 3 Interventional Results available

Late-onset Sepsis in Term and Pre-term Neonates and Infants up to 3 Months of Age

NCT05856227
View directory record Official record
Conditions
Neonatal Sepsis
Interventions
Ceftobiprole medocaril
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
3 Days to 3 Months
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Evanston, Illinois • Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 22, 2026, 11:57 PM EDT
Completed Not applicable Interventional

Prone or Supine Effect After Caesarean Delivery on Respiratory Outcomes in Full Term Infants

NCT02692573
View directory record Official record
Conditions
Prone vs Supine Effects on Respiratory Outcomes
Interventions
positioning
Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Oct 22, 2026, 11:57 PM EDT
Terminated Phase 4 Interventional Results available

Clonidine as Adjunct to Morphine for Neonatal Abstinence Syndrome

NCT03762317
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
Clonidine, Placebo
Drug
Lead sponsor
Hennepin County Medical Center, Minneapolis
Other
Eligibility
36 Weeks to 45 Weeks
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 10, 2023 · Synced Oct 22, 2026, 11:57 PM EDT
Withdrawn Not applicable Interventional

Non-inflatable Supraglottic Airway (NI-SGA) vs. Face Mask (FM) as a Primary Interface Device for Neonatal Resuscitation

NCT02629887
View directory record Official record
Conditions
Neonatal Resuscitation
Interventions
Non-inflatable supraglottic airway, Face Mask, T-Piece Resuscitator
Device
Lead sponsor
University of Oklahoma
Other
Eligibility
Up to 30 Minutes
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 9, 2018 · Synced Oct 22, 2026, 11:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Growth and Safety of a Low Lactose Milk-Based Infant Formula

NCT01497314
View directory record Official record
Conditions
Growth, Healthy Term Infants
Interventions
Low Lactose Infant Formula
Other
Lead sponsor
Perrigo Nutritionals
Industry
Eligibility
Up to 14 Days
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
6
States / cities
Melbourne, Florida • Haughton, Louisiana • Kansas City, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated May 15, 2013 · Synced Oct 22, 2026, 11:57 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neuroendocrine Mechanisms of Growth and Body Composition in Preterm and Term Infants

NCT00833222
View directory record Official record
Conditions
Premature Birth
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
31 Weeks to 42 Weeks
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 26, 2017 · Synced Oct 22, 2026, 11:57 PM EDT
Completed Phase 3 Interventional Results available

Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation

NCT01707290
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
6 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
33
States / cities
Birmingham, Alabama • Palo Alto, California • Denver, Colorado + 30 more
Source: ClinicalTrials.gov public record
Updated May 12, 2017 · Synced Oct 22, 2026, 11:57 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Comparative Gastrointestinal Tolerance of Various Infant Formulas in Healthy Term Infants

NCT00798382
View directory record Official record
Conditions
Infant, Newborn
Interventions
soy protein formula, Commercially available soy formula, Soy formula experimental #2
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
Up to 8 Days
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
17
States / cities
Little Rock, Arkansas • Plantation, Florida • St. Petersburg, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2012 · Synced Oct 22, 2026, 11:57 PM EDT
Completed Phase 3 Interventional Results available

Short-Term vs. Long-Term Valganciclovir Therapy for Symptomatic Congenital CMV Infections

NCT00466817
View directory record Official record
Conditions
Cytomegalovirus Infection
Interventions
Placebo, Valganciclovir
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 30 Days
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
41
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2015 · Synced Oct 22, 2026, 11:57 PM EDT
Not listed No phase listed Observational

Unbound Bilirubin Levels in Healthy Term and Late Preterm Infants

NCT03237715
View directory record Official record
Conditions
Neonatal Jaundice
Interventions
Assessment of unbound bilirubin levels
Other
Lead sponsor
Rutgers University
Other
Eligibility
6 Hours to 7 Days
Enrollment
180 participants
Timeline
2017 – 2019
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 2, 2017 · Synced Oct 22, 2026, 11:57 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Infant Immune Response to Bacterial Infection

NCT00546195
View directory record Official record
Conditions
Prematurity, Histologic Chorioamnionitis
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Not listed
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 22, 2026, 11:57 PM EDT
Completed Phase 3 Interventional Results available

Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor

NCT02544451
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
LUM/IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
6 Years and older
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
37
States / cities
Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Oct 22, 2026, 11:57 PM EDT
Completed Phase 1Phase 2 Interventional Results available

How Pregnant Women and Their Babies Metabolize Ondansetron Compared to a Group of Non-pregnant Women

NCT01801475
View directory record Official record
Conditions
Postoperative Nausea
Interventions
Ondansetron
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Oct 22, 2026, 11:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Growth, Safety, and Efficacy of an Infant Formula for Healthy Term Infants

NCT04218929
View directory record Official record
Conditions
Infants, Newborn
Interventions
Study Formula (SF), Comparator Formula (CF)
Other
Lead sponsor
ByHeart
Industry
Eligibility
0 Days to 14 Days
Enrollment
311 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
27
States / cities
Birmingham, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 22, 2026, 11:57 PM EDT
Completed Not applicable Interventional

Medium-term Venous Access in Congenital Heart Surgery

NCT00852488
View directory record Official record
Conditions
Congenital Heart Surgery
Interventions
Placement of transthoracic catheter
Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
1 Day to 365 Days
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Oct 22, 2026, 11:57 PM EDT
Active, not recruiting No phase listed Observational

Extension Study to Evaluate the Long-Term Outcomes of Pediatric Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study (Acronym: Butterfleye Next)

NCT04515524
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
Non-Interventional
Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
11 Months to 5 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
9
States / cities
La Jolla, California • Loma Linda, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 22, 2026, 11:57 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study Evaluating Prevnar Infant Long-term Immune Response Versus Prevnar Naive Cohort

NCT00824850
View directory record Official record
Conditions
Pneumococcal Conjugate Vaccine
Interventions
13-valent Pneumococcal Conjugate Vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
8 Years to 16 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
2
States / cities
Hayward, California • San Jose, California
Source: ClinicalTrials.gov public record
Updated Nov 11, 2011 · Synced Oct 22, 2026, 11:57 PM EDT
Recruiting No phase listed Observational

Bempedoic Acid Pregnancy Surveillance Program

NCT05103254
View directory record Official record
Conditions
Pregnancy, Hyperlipidemias
Interventions
Bempedoic Acid, Bempedoic Acid / Ezetimibe
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Timeline
2021 – 2032
U.S. locations
1
States / cities
Morrisville, North Carolina
Source: ClinicalTrials.gov public record
Updated May 17, 2024 · Synced Oct 22, 2026, 11:57 PM EDT